Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin Lymphoma

Anas Younes, MD
Published Online: Thursday, August 28, 2014
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

The current standard of care for patients with classical Hodgkin lymphoma is ABVD. A phase I trial that combined AVD with brentuximab vedotin showed promising safety and efficacy results.

The Echelon-1 study is a large, randomized trial aiming to compare ABVD with AVD plus brentuximab. The primary endpoint of the trial is modified progression-free survival: death, progression, receipt of chemotherapy or radiotherapy by patients not in complete response after completing front-line therapy.

Results of this trial could change practice, Younes says.

Online CME Activities
Free CME from PER
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
OncoLogue: Breast Cancer Cases
More Reading
Publications
$auto_registration$